These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

430 related articles for article (PubMed ID: 33616890)

  • 1. Novel Therapy Approaches to Follicular Lymphoma.
    Northend M; Townsend W
    Drugs; 2021 Mar; 81(4):453-469. PubMed ID: 33616890
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Matching-Adjusted Indirect Comparison of Single-Arm Trials in Patients with Relapsed or Refractory Follicular Lymphoma Who Received at Least Two Prior Systemic Treatments: Tazemetostat was Associated with a Lower Risk for Safety Outcomes Versus the PI3-Kinase Inhibitors Idelalisib, Duvelisib, Copanlisib, and Umbralisib.
    Proudman D; Nellesen D; Gupta D; Adib D; Yang J; Mamlouk K
    Adv Ther; 2022 Apr; 39(4):1678-1696. PubMed ID: 35157216
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Follicular lymphoma: The long and winding road leading to your cure?
    Gordon MJ; Smith MR; Nastoupil LJ
    Blood Rev; 2023 Jan; 57():100992. PubMed ID: 35908982
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advancements in the Management of Follicular Lymphoma: A Comprehensive Review.
    Merryman R; Mehtap Ö; LaCasce A
    Turk J Haematol; 2024 May; 41(2):69-82. PubMed ID: 38660754
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Follicular Lymphoma: a Focus on Current and Emerging Therapies.
    Cahill KE; Smith SM
    Oncology (Williston Park); 2022 Feb; 36(2):97-106. PubMed ID: 35180337
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evolving therapeutic landscape in follicular lymphoma: a look at emerging and investigational therapies.
    Hanel W; Epperla N
    J Hematol Oncol; 2021 Jun; 14(1):104. PubMed ID: 34193230
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thinking "outside the germinal center": Re-educating T cells to combat follicular lymphoma.
    Thiruvengadam SK; Shouse G; Danilov AV
    Blood Rev; 2023 Sep; 61():101099. PubMed ID: 37173225
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Refining the management of relapsed or refractory follicular lymphoma.
    Pagel JM; Burke JM; Leslie LA
    Clin Adv Hematol Oncol; 2020 Dec; 18 Suppl 20(12):1-24. PubMed ID: 33843893
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mosunetuzumab and the emerging role of T-cell-engaging therapy in follicular lymphoma.
    Matarasso S; Assouline S
    Future Oncol; 2023 Oct; 19(31):2083-2101. PubMed ID: 37882361
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Current standard treatments and future outlook for follicular lymphoma].
    Maruyama D
    Rinsho Ketsueki; 2024; 65(9):1004-1011. PubMed ID: 39358254
    [TBL] [Abstract][Full Text] [Related]  

  • 11. When to Use Targeted Therapy for the Treatment of Follicular Lymphoma.
    Nastoupil LJ
    Curr Hematol Malig Rep; 2021 Feb; 16(1):45-51. PubMed ID: 33797691
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeted Therapies for Follicular Lymphoma.
    Girard J; Karimi Y; Carty S; Wilcox R; Kaminiski M; Malek S; Phillips T
    Curr Hematol Malig Rep; 2021 Feb; 16(1):25-31. PubMed ID: 33754292
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination lenalidomide-rituximab immunotherapy activates anti-tumour immunity and induces tumour cell death by complementary mechanisms of action in follicular lymphoma.
    Chiu H; Trisal P; Bjorklund C; Carrancio S; Toraño EG; Guarinos C; Papazoglou D; Hagner PR; Beldi-Ferchiou A; Tarte K; Delfau-Larue MH; Morschhauser F; Ramsay AG; Gandhi AK
    Br J Haematol; 2019 Apr; 185(2):240-253. PubMed ID: 30767211
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treating relapsed follicular lymphoma.
    Erblich T; Montoto S
    Expert Rev Hematol; 2018 May; 11(5):403-410. PubMed ID: 29542329
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-dose therapy with autologous stem cell transplantation versus chemotherapy or immuno-chemotherapy for follicular lymphoma in adults.
    Schaaf M; Reiser M; Borchmann P; Engert A; Skoetz N
    Cochrane Database Syst Rev; 2012 Jan; 1(1):CD007678. PubMed ID: 22258971
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and tolerability of idelalisib, lenalidomide, and rituximab in relapsed and refractory lymphoma: the Alliance for Clinical Trials in Oncology A051201 and A051202 phase 1 trials.
    Smith SM; Pitcher BN; Jung SH; Bartlett NL; Wagner-Johnston N; Park SI; Richards KL; Cashen AF; Jaslowski A; Smith SE; Cheson BD; Hsi E; Leonard JP
    Lancet Haematol; 2017 Apr; 4(4):e176-e182. PubMed ID: 28314699
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Front-line management of non-Hodgkin lymphoma in Australia. Part 1: follicular lymphoma.
    Trotman J; Cheah CY; Marlton P; Opat S
    Intern Med J; 2019 Apr; 49(4):422-433. PubMed ID: 30230156
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recent landmark studies in follicular lymphoma.
    Sorigue M; Sancho JM
    Blood Rev; 2019 May; 35():68-80. PubMed ID: 30928169
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New developments in the treatment of follicular lymphoma.
    Leonard JP
    Rinsho Ketsueki; 2019; 60(9):1199-1204. PubMed ID: 31597844
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Translational insights into the genetics and immunobiology of relapsed/refractory follicular lymphoma.
    Yaniv B; Tanenbaum B; Kazakova V; Patel SA
    Leuk Res; 2024 Jul; 142():107519. PubMed ID: 38761562
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.